Oncogenic mutations in epidermal growth factor receptor (EGFR) are used as predictive biomarkers for using EGFR TKI as a treatment strategy for non-small cell lung cancer (NSCLC) [1, 2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.